Editas Medicine

Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and a non-exclusive license for AsCas12a Shoreline to acquire…

EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant Both patients treated with EDIT-301 successfully engrafted and are…

Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement protein levels using a dual vector AAV approach Treated eyes showed morphological and functional…

Successful engraftment of first patient dosed with EDIT-301 for sickle cell disease FDA removed partial clinical hold for the RUBY trial in EDIT-301  First clinical use of Editas-engineered AsCas12a enzyme  Initial clinical data from…

Studies in non-human primates demonstrated nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels Treated eyes showed morphological and functional photoreceptor preservation …

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that four abstracts have been accepted for presentation, including three oral presentations, at…

Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a potential therapeutic approach for solid tumors iNKs with double knock-in of CD16 and…

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical data from the BRILLIANCE clinical trial of EDIT-101…

No serious adverse events or dose-limiting toxicities observed to date Efficacy signals in the mid-dose cohort provide initial support for clinical benefits Treatment in the adult high-dose cohort continues and pediatric mid-dose cohort…

Data to include patient safety assessments and a preliminary analysis of secondary endpoints to evaluate biological activity Abstract selected for oral presentation on September 29 Company to host webcast investor event following the…